论文部分内容阅读
最近的研究结果证实慢性乙型肝炎患者血清中存在的HBV RNA为3.5 kb的前基因组RNA(pgRNA),这些pgRNA存在于形态结构类似于丹颗粒的病毒样颗粒中。由于pgRNA只能由位于感染的肝细胞核内的病毒共价闭合环状DNA(cccDNA),且其产生过程不受核苷(酸)类抗病毒药物的影响,因此血清病毒RNA应能够反映接受治疗的患者肝细胞内cccDNA的存在及转录活性。据此推测,血清病毒RNA可作为一个潜在的指导核苷(酸)类似物安全停药的指标。基于小样本停药队列研究的结果显示停药点血清中HBV RNA的确与慢性乙型肝炎停药后的病毒学反弹相关。
Recent findings confirm the presence of HBV RNA in the serum of patients with chronic hepatitis B as 3.5 kb pregenomic RNA (pgRNA) that is found in virus-like particles that morphologically resemble Dan particles. Since pgRNA can only covalently close the circular DNA (cccDNA) by the virus located in the infected hepatocyte nucleus and its production is not affected by the nucleoside (an) antiviral drug, the serum viral RNA should be able to reflect the effect of receiving treatment Of patients with hepatocellular cccDNA and transcriptional activity. Therefore, it is speculated that serum viral RNA may serve as a potential indicator of safe withdrawal of nucleoside (acid) analogues. Results from a small sample-based cohort study showed that serum HBV RNA did not correlate with virological rebound after chronic hepatitis B withdrawal.